LumibirdHAM:QTL -3.93%65 Net Margin % is 7.56% as of Dec. 2025, which is 26% above its 10-year median of 5.99. GuruFocus rates HAM:QTL with a GF Score™ of 65/100 and a GF Value™ of €16.32 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Lumibird ranks better than 66.67% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Lumibird's Net Income for the
six
months ended in Dec. 2025 was €9.1 Mil. Lumibird's Revenue for the
six
months ended in Dec. 2025 was €120.2 Mil. Therefore, Lumibird's net margin for the quarter that ended in Dec. 2025 was 7.56%.
The historical rank and industry rank for Lumibird's Net Margin % or its related term are showing as below:
HAM:QTL'
s Net Margin % Range Over the Past 10 Years
Min: 2.71 Med: 5.99 Max: 12.32
Current: 6.13
HAM:QTL's Net Margin % is ranked better than 66.67% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -2.405
vs HAM:QTL: 6.13
Lumibird (HAM:QTL) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Lumibird Net Margin % Related Terms
Lumibird Net Margin % Historical Data
* Premium members only.
The historical data trend for Lumibird's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HAM:QTL vs TMO, DHR, IDXX: Net Margin % Comparison
For the Diagnostics & Research subindustry, Lumibird's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lumibird Net Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lumibird's Net Margin % distribution charts can be found below:
* The bar in red indicates where Lumibird's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lumibird (HAM:QTL) has a Net Margin % of 7.56% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on Lumibird and its competitors. This is 26% above median its historical median of 5.99. Over the past decade, Lumibird's Net Margin % has ranged from 2.71 to 12.32. According to the industry distribution chart, Lumibird ranks #68 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 33.3%.
Is Lumibird's Net Margin % too high?
Lumibird's current Net Margin % of 7.56% is 26% above median its 10-year median of 5.99. Over the past 10 years, this metric has ranged from a low of 2.71 to a high of 12.32. Based on the distribution chart, Lumibird ranks #68 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Lumibird has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lumibird's Net Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lumibird ranks #68 out of 204 companies for Net Margin %. This puts Lumibird in the upper half of its industry. Historically, Lumibird's own Net Margin % has ranged from 2.71 to 12.32 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Diagnostics & Research company?
A good Net Margin % depends on the Medical Diagnostics & Research industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Lumibird and its competitors. Lumibird's current Net Margin % is 7.56%, which is 26% above median its own 10-year median of 5.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lumibird stock overvalued right now?
Based on GuruFocus' analysis, Lumibird (HAM:QTL) is currently considered Significantly Overvalued. The stock's GF Value™ is €16.32, compared to a current price of €23.25 — trading 42.5% above its estimated fair value. The current Net Margin % is 7.56%, which is 26% above median its 10-year median of 5.99. Lumibird's overall GF Score™ is 65/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Lumibird (HAM:QTL), the current Net Margin % is 7.56% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lumibird (HAM:QTL) Overvalued in 2026?
Based on GuruFocus' analysis, Lumibird stock appears to be overvalued.
The current stock price of €23.25 is trading 42.5% above its estimated GF Value™ of €16.32.
GuruFocus considers Lumibird to be Significantly Overvalued.
Key valuation signals for HAM:QTL:
Net Margin %: 7.56% (26% above median its 10-year median of 5.99)
GF Value™: €16.32 vs. price of €23.25 (42.5% above fair value)
No single metric tells the full story. See the HAM:QTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lumibird, formerly Quantel SA is an enterprise engaged in the designing, manufacturing, and sale of scientific laser solutions. Scientific and industrial applications lasers used by research laboratories in the study of material, cleaning lasers, marking, measurement, and others. whereas, Medical applications include specialized lasers for ophthalmology, dermatology, and esthetics. The company generates a majority of its revenue from the scientific and industrial applications.
65GF Score
Get the complete analysis for HAM:QTL
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:QTL has been successfully added to your 
